Clinical research is evolving rapidly. While randomised controlled trials (RCTs) remain the gold standard for establishing the safety and efficacy of new therapies, there is increasing recognition that understanding how treatments perform in real-world clinical settings is equally important.
This shift has accelerated the use of real-world evidence (RWE) in drug development. Regulatory bodies, including the FDA and EMA, are increasingly incorporating real-world evidence into their frameworks, particularly in areas such as oncology and rare diseases.
However, the conversation is no longer about choosing between RWE and RCTs. Instead, modern clinical development increasingly relies on the intelligent integration of both approaches to generate a more complete understanding of treatment effectiveness and patient outcomes.
What Is Real-World Evidence (RWE)?
Real-world evidence refers to the clinical evidence generated through the analysis of real-world data (RWD). Unlike traditional clinical trial data collected under highly controlled conditions, RWE reflects how treatments perform in routine clinical practice across broader and more diverse patient populations.
Real-world evidence can provide valuable insights into treatment effectiveness, long-term safety, healthcare utilisation, and patient experiences outside the controlled environment of a conventional clinical trial.
What Is Real-World Data (RWD)?
Real-world data is health-related data collected outside of traditional interventional clinical trials. Sources of RWD can include:
- Electronic health records (EHRs)
- Insurance and claims databases
- Patient registries
- Wearable devices and digital health technologies
- Mobile health applications
- Electronic patient-reported outcomes (ePROs)
- Pharmacy and prescribing databases
These sources allow researchers to capture data from routine clinical practice, often across larger and more representative patient populations than those included in traditional RCTs.
How Is RWE Generated?
Real-world evidence is produced by aggregating and analysing real-world data using epidemiological and statistical methodologies. Depending on the research question, this may involve observational studies, retrospective database analyses, pragmatic trials, or external control arms.
Importantly, raw data alone does not constitute evidence. The reliability of RWE depends heavily on the quality of the data source, study design, analytical methods, and management of bias and confounding factors.
What Are Randomised Controlled Trials (RCTs)?
Randomised controlled trials are prospective clinical studies designed to evaluate the safety and efficacy of investigational therapies under controlled conditions.
Participants are randomly assigned to treatment groups, helping minimise bias and enabling stronger causal interpretation of outcomes. RCTs also typically use strict inclusion and exclusion criteria to reduce variability and improve internal validity.
Because of this rigorous design, RCTs remain central to regulatory approval pathways and are widely regarded as the gold standard for demonstrating treatment efficacy.
However, the controlled nature of RCTs can also create limitations. Trial populations may not fully reflect the broader patient populations seen in routine clinical practice, particularly older adults, patients with multiple comorbidities, or underrepresented demographic groups.
RWE vs RCT: What’s the Difference?
Although both approaches generate valuable evidence, RWE and RCTs are designed to answer different questions.
Randomised controlled trials are conducted in controlled environments using randomisation to minimise bias and determine whether a treatment works under ideal conditions. They typically involve narrower patient populations and prioritise internal validity to support regulatory approval.
Real-world evidence, by contrast, reflects how treatments perform in routine clinical practice. Using observational data from broader and more diverse patient populations, RWE provides insight into treatment effectiveness, long-term outcomes, and patient experiences outside controlled study settings.
Put simply:
- RCTs help determine whether a treatment can work under controlled conditions
- RWE helps determine how a treatment performs in everyday clinical practice
Increasingly, these approaches are viewed as complementary rather than competing, with both contributing to a more complete understanding of treatment safety and effectiveness.
Why Is Real-World Evidence Becoming More Important in Clinical Trials?
Broader and More Representative Patient Populations
Traditional RCTs often exclude patients with complex medical histories, multiple comorbidities, or concurrent treatments. While this improves study control, it can reduce generalisability.
RWE helps bridge this gap by capturing outcomes from broader patient populations that more accurately reflect routine clinical practice.
Improving Trial Efficiency and Recruitment
Real-world data can support clinical trial planning and operational efficiency by helping researchers assess protocol feasibility, identify patient populations, optimise inclusion criteria, and improve recruitment strategies.
These insights can help reduce recruitment delays and improve study efficiency.
Supporting Long-Term Safety Monitoring
RCTs are often limited in duration and sample size, meaning rare adverse events or long-term outcomes may not emerge until after approval.
RWE plays an important role in post-marketing surveillance and pharmacovigilance by enabling continuous monitoring of treatment safety and effectiveness.
Enabling Research in Rare Diseases and Oncology
In rare diseases and certain oncology settings, large-scale randomised trials may be impractical or ethically challenging.
In these scenarios, RWE can provide contextual data and support alternative study designs when traditional comparators are difficult to establish.
How Is Real-World Evidence Used Across Clinical Development?
Trial Design and Feasibility
RWD can help sponsors assess eligibility criteria, estimate patient populations, and evaluate recruitment feasibility.
This allows for more practical and patient-centred trial designs.
External and Synthetic Control Arms
One of the most rapidly evolving applications of RWE is the use of external or synthetic control arms.
These approaches use historical clinical trial data and real-world data to create comparator groups when placebo or standard-of-care control arms may be difficult or unethical.
Post-Marketing Surveillance and Pharmacovigilance
RWE is widely used to support ongoing safety monitoring following regulatory approval by identifying adverse events, monitoring adherence patterns, and assessing outcomes across different patient populations.
Regulatory and HTA Decision-Making
Regulators increasingly acknowledge the value of RWE in supporting approval decisions, label expansions, reimbursement discussions, and health technology assessments.
Can Real-World Evidence Replace RCTs?
In most cases, no. Randomised controlled trials remain essential for establishing causal relationships and supporting regulatory approval. Their controlled design remains critical for reducing bias.
However, RWE can complement traditional trials by providing additional context around treatment effectiveness, safety, and patient outcomes in routine practice.
In some circumstances, particularly rare diseases, oncology, or situations where placebo control may be unethical , RWE may reduce reliance on traditional control arms or supplement conventional trial evidence.
The future of clinical development is therefore unlikely to involve replacing RCTs with RWE. Instead, the industry is moving toward integrated evidence generation strategies that combine the strengths of both approaches.
The Future of RWE in Clinical Trials
Wearable devices, digital health technologies, artificial intelligence, machine learning, and advanced analytics are expanding the potential of real-world evidence.
At the same time, pragmatic trials and decentralised study models are helping bridge the gap between tightly controlled clinical research and routine clinical practice.
As regulators, sponsors, and healthcare providers continue to embrace these innovations, RWE is expected to play an increasingly important role in delivering more efficient, patient-centred, and data-driven drug development.
Conclusion
Real-world evidence is reshaping how treatments are evaluated across the clinical development lifecycle. While RCTs remain foundational to demonstrating efficacy and supporting regulatory approval, RWE provides critical insight into how therapies perform in everyday clinical practice.
Rather than competing approaches, RWE and RCTs provide complementary forms of evidence that together create a more complete understanding of treatment safety, effectiveness, and patient outcomes.
As clinical research continues to evolve, integrating robust real-world evidence alongside traditional trial methodologies will become increasingly important in delivering more efficient and patient-centred drug development.
How Simbec-Orion Can Support Your Programme
Successfully integrating real-world evidence into clinical development requires more than access to data alone. Generating meaningful evidence demands the right combination of scientific, operational, and regulatory expertise.
At Simbec-Orion, we support sponsors through the design and delivery of complex clinical programmes with expertise spanning early phase development, clinical operations, biometrics, pharmacovigilance, and regulatory strategy.
Our integrated approach helps ensure real-world evidence generation is scientifically robust, operationally feasible, and aligned with development objectives.
Contact our expert team today to discuss how we can support your clinical development programme.